Cutting-edge AI technology developed by diagnostics expert MI:RNA offers promising outcomes for cats and dogs diagnosed with heart disease, potentially elongating their lives by up to 18 months.
Present testing standards tend to overlook early indications of heart disease in about 9 out of 10 cases, but MI:RNA’s diagnostic technology boasts an 85 percent sensitivity and 83 percent accuracy rate in identifying prevalent diseases like mitral valve disease (MMVD), even in the initial stages.
MI:RNA’s NEMO Cardiac Health Screening test employs microRNA analysis—a novel biomarker linked to disease evolution and resolution—to identify heart diseases earlier in pets. Through AI integration, this innovative approach significantly enhances the early detection of complex conditions like MMVD, allowing pets prompt access to optimal care.
Mitral valve disease often leads to heart failure, displaying symptoms such as reduced exercise capacity, coughing, restlessness, and breathing difficulties. The initial phases often show minimal symptoms, extending over months or even years. By detecting MMVD in its early stages, MI:RNA’s microRNA profiling and AI algorithms enable veterinarians to diagnose and monitor disease progression more effectively, assisting pet owners and breeders in directing appropriate care and resources.
Pioneering Disease Detection
Eve Hanks, the founder and CEO of MI:RNA, highlights the importance of this technology, particularly for dogs, stating, “MMVD is the most prevalent cardiovascular disease in canines, affecting approximately 10% of dogs in primary care veterinary practices, with up to 60% prevalence in older dogs. Innovative tools like microRNA profiling, backed by robust AI algorithms, are pivotal in diagnosing and staging MMVD accurately.”
Professor Joanna Dukes-McEwan, a veterinary cardiology professor at the University of Liverpool, emphasizes the practicality of MI:RNA panels for primary care vets, saying, “A simple blood test confirming the presence and severity of cardiac diseases like MVD could greatly aid primary care vets in assessing their patients’ needs for specialized treatment or referral.”
The scope of the AI technology extends beyond heart diseases, offering early detection possibilities for epilepsy, kidney disease, intestinal diseases, and cancer in pets. MI:RNA’s precision medicine in veterinary diagnostics holds promise for breeders and pet owners in identifying affected animals promptly, offering targeted interventions and potentially transforming outcomes for pets suffering from various diseases.
